Trials / Recruiting
RecruitingNCT07202364
A Study of YL202 in Patients With Advanced Solid Tumors
A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Detailed description
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the advanced non small cell lung cancer/colorectal cancer/cervical cancer, etc. YL202 is an antibody-drug conjugate (ADC) that targets HER3 protein
Conditions
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Locally Advanced or Metastatic Solid Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YL202 | YL202 will be intravenously infused over 60±10 min |
Timeline
- Start date
- 2025-08-04
- Primary completion
- 2026-08-31
- Completion
- 2027-02-28
- First posted
- 2025-10-01
- Last updated
- 2026-03-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07202364. Inclusion in this directory is not an endorsement.